FDA committee to discuss dapagliflozin

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Dec. 12 to discuss a resubmitted NDA from Bristol-Myers Squibb Co. (NYSE:BMY) for Forxiga dapagliflozin to treat Type II diabet...